Rizatriptan Benzoate Tablet
Product Images NDC 50090-3367

5 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 50090-3367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500903367)

Label Image (Lbl500903367)
Rizatriptan Benzoate 10 mg oral tablet packaging label from A-S Medication Solutions. The label displays active ingredient strength, product number, storage instructions (store at 68 to 77 degrees F), and packaging details of 18 tablets distributed in 3 blister cards of 6 tablets each. The NDC number 50090-3367-0 is also visible.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response by 2 hours post-dose. The X-axis represents hours post-dose (0 to 2), and the Y-axis shows the estimated probability of response (0% to 100%). The chart compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg across pooled data from four outpatient trials.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
Kaplan-Meier plot showing the estimated probability over 24 hours post-dose of patients taking a second dose of Rizatriptan Benzoate tablets or other medication for migraines. The graph compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg groups in pooled studies 1, 2, 3, and 4, with estimated probability on the vertical axis and hours post-dose on the horizontal axis.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)
Line graph showing observed percentage of patients reporting no headache pain up to 2 hours after dosing in Study 7. It compares Rizatriptan Benzoate orally disintegrating tablets to placebo, plotting percentage on the y-axis and hours post dose on the x-axis, with Rizatriptan showing higher percentages than placebo at each time point.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure diagram of Rizatriptan Benzoate showing its molecular components including a triazole ring, an indole moiety, and a benzoic acid group as part of the benzoate salt.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.